| Literature DB >> 33228208 |
Przemysław Kapusta1, Joanna Dulińska-Litewka2, Justyna Totoń-Żurańska1, Agnieszka Borys1, Paweł S Konieczny1, Paweł P Wołkow1,3, Michał T Seweryn1,4.
Abstract
The reciprocal interactions between cancer cells and the quiescent fibroblasts leading to the activation of cancer-associated fibroblasts (CAFs) serve an important role in cancer progression. Here, we investigated the activation of transcription factors (TFs) in prostate fibroblasts (WPMY cell line) co-cultured with normal prostate or tumorous cells (RWPE1 and RWPE2 cell lines, respectively). After indirect co-cultures, we performed mRNA-seq and predicted TF activity using mRNA expression profiles with the Systems EPigenomics Inference of Regulatory Activity (SEPIRA) package and the GTEx and mRNA-seq data of 483 cultured fibroblasts. The initial differential expression analysis between time points and experimental conditions showed that co-culture with normal epithelial cells mainly promotes an inflammatory response in fibroblasts, whereas with the cancerous epithelial, it stimulates transformation by changing the expression of the genes associated with microfilaments. TF activity analysis revealed only one positively regulated TF in the RWPE1 co-culture alone, while we observed dysregulation of 45 TFs (7 decreased activity and 38 increased activity) uniquely in co-culture with RWPE2. Pathway analysis showed that these 45 dysregulated TFs in fibroblasts co-cultured with RWPE2 cells may be associated with the RUNX1 and PTEN pathways. Moreover, we showed that observed dysregulation could be associated with FER1L4 expression. We conclude that phenotypic changes in fibroblast responses to co-culturing with cancer epithelium result from orchestrated dysregulation of signaling pathways that favor their transformation and motility rather than proinflammatory status. This dysregulation can be observed both at the TF and transcriptome levels.Entities:
Keywords: FER1L4; cancer-associated fibroblasts (CAFs); long non-coding RNA (lncRNA); prostate cancer; transcription factors (TFs)
Mesh:
Substances:
Year: 2020 PMID: 33228208 PMCID: PMC7699520 DOI: 10.3390/ijms21228749
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1Differentially expressed (DE) gene analysis between 6 and 24 h in each condition separately. Volcano plots represents the distribution of DE genes between 6 and 24 h for the control (CTRL) (A), WR1 (B) and WR2 (C) groups. Lines separate logFC > 1 and adj. p value < 0.05. Venn diagram of the distribution of DE genes between 6 and 24 h in each condition with logFC > 1 (D). Red color represents upregulated genes, and blue, downregulated genes.
Top10 gene ontologies (GOs) for gene enrichment analysis of DE genes with logFC > 1 unique for WR1 and WR2 conditions.
| Condition | GO.ID | Term | Annotated_Genes | |
|---|---|---|---|---|
| WR1 | GO:0019221 | Cytokine-mediated signaling pathway | 2.50 × 10−4 | |
| GO:0071222 | Cellular response to lipopolysaccharide | 8.30 × 10−4 | ||
| GO:0015804 | neutral amino acid transport | 1.22 × 10−3 | ||
| GO:0006855 | Drug transmembrane transport | 2.12 × 10−3 | ||
| GO:0071356 | Cellular response to tumor necrosis factor | 2.51 × 10−3 | ||
| GO:0019724 | B cell-mediated immunity | 3.50 × 10−3 | ||
| GO:0009605 | Response to external stimulus | 3.59 × 10−3 | ||
| GO:0019730 | Antimicrobial humoral response | 3.67 × 10−3 | ||
| GO:0061469 | Regulation of type B pancreatic cell proliferation | 4.12 × 10−3 | ||
| GO:0032354 | Response to follicle-stimulating hormone | 4.12 × 10−3 | ||
| WR2 | GO:0001541 | Ovarian follicle development | 3.30 × 10−5 | |
| GO:0045987 | Positive regulation of smooth muscle contraction | 6.50 × 10−4 | ||
| GO:0060285 | Cilium-dependent cell motility | 9.90 × 10−4 | ||
| GO:0003341 | Cilium movement | 3.67 × 10−3 | ||
| GO:0042745 | Circadian sleep/wake cycle | 3.89 × 10−3 | ||
| GO:0099175 | Regulation of post-synapse organization | 4.04 × 10−3 | ||
| GO:0045747 | Positive regulation of Notch signaling pathway | 4.29 × 10−3 | ||
| GO:1900029 | Positive regulation of ruffle assembly | 4.64 × 10−3 | ||
| GO:0045986 | Negative regulation of smooth muscle contraction | 4.64 × 10−3 | ||
| GO:0051290 | Protein heterotetramerization | 4.96 × 10−3 |
GO.ID—The Gene Ontology Identifier.
Figure 2Nominally significant changes of transcription factor (TF) activity in separate comparisons of WR1 vs. WR2 group at 6 (A) or 24 h (B–D) time points. (A) THRAP3; (B) SNAPC1; (C) GTF3C1; (D) RNF4.
Figure 3Venn diagram of TFs that changed activity between the 6 and 24 h time points.
Reactome analysis of unique TFs for 6 vs. 24 h time points in the WR2 condition.
| Pathway Identifier | Pathway Name | Entities | Entities FDR | TFs |
|---|---|---|---|---|
| R-HSA-8953750 | Transcriptional Regulation by E2F6 | 2.14 × 10−5 | 2.66 × 10−3 | YAF2, EED, CBX5 |
| R-HSA-8939243 | RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known | 3.55 × 10−4 | 2.20 × 10−2 | YAF2, SMARCE1, SMARCA2 |
| R-HSA-8943724 | Regulation of PTEN gene transcription | 1.90 × 10−3 | 4.68 × 10−2 | EED, REST, SNAI2 |
| R-HSA-3247509 | Chromatin modifying enzymes | 1.95 × 10−3 | 4.68 × 10−2 | SMARCE1, EED, SMARCA2, REST, KDM5A |
| R-HSA-4839726 | Chromatin organization | 1.95 × 10−3 | 4.68 × 10−2 | SMARCE1, EED, SMARCA2, REST, KDM5A |
FDR—false discovery rate; TFs—transcription factors.
Figure 4Expression of FER1L4 measured by RT-qPCR in experimental conditions after 24 h of co-culture. (* p < 0.05 by Kruskal–Wallis test).
The top 10 KEGG pathways enriched by the target genes of 27 micro RNAs (miRNAs) with experimentally supported interaction with FER1L4.
| KEGG Pathway | FDR | Number of Genes | Number of miRNAs | |
|---|---|---|---|---|
| ECM-receptor interaction (hsa04512) | 6.09 × 10−20 | 1.23 × 10−17 | 11 | 18 |
| Signaling pathways regulating pluripotency of stem cells (hsa04550) | 6.91 × 10−6 | 6.97 × 10−4 | 18 | 22 |
| Mucin type O-Glycan biosynthesis (hsa00512) | 6.62 × 10−5 | 3.63 × 10−3 | 4 | 12 |
| Focal adhesion (hsa04510) | 8.23 × 10−5 | 3.63 × 10−3 | 23 | 20 |
| PI3K-Akt signaling pathway (hsa04151) | 9.13 × 10−5 | 3.63 × 10−3 | 32 | 23 |
| Lysine degradation (hsa00310) | 1.08 × 10−4 | 3.63 × 10−3 | 5 | 24 |
| Glioma (hsa05214) | 2.14 × 10−4 | 6.16 × 10−3 | 8 | 19 |
| Glycosphingolipid biosynthesis—lacto and neolacto series (hsa00601) | 2.95 × 10−4 | 7.46 × 10−3 | 3 | 12 |
| Adipocytokine signaling pathway (hsa04920) | 6.49 × 10−4 | 1.24 × 10−2 | 10 | 17 |
| TGF-beta signaling pathway (hsa04350) | 7.09 × 10+ | 1.24 × 10−2 | 10 | 19 |
| Protein digestion and absorption (hsa04974) | 7.10 × 10−4 | 1.24 × 10−2 | 12 | 19 |
| MAPK signaling pathway (hsa04010) | 7.37 × 10−4 | 1.24 × 10−2 | 23 | 23 |
| Nicotine addiction (hsa05033) | 1.05 × 10−3 | 1.63 × 10−2 | 5 | 17 |
| AMPK signaling pathway (hsa04152) | 1.55 × 10−3 | 2.24 × 10−2 | 13 | 17 |
| mTOR signaling pathway (hsa04150) | 1.75 × 10−3 | 2.36 × 10−2 | 9 | 18 |
| ErbB signaling pathway (hsa04012) | 1.96 × 10−3 | 2.48 × 10−2 | 10 | 21 |
| Amoebiasis (hsa05146) | 2.23 × 10−3 | 2.63 × 10−2 | 7 | 13 |
| Melanoma (hsa05218) | 2.35 × 10−3 | 2.63 × 10−2 | 9 | 19 |
| Proteoglycans in cancer (hsa05205) | 2.69 × 10−3 | 2.86 × 10−2 | 16 | 20 |
| Pancreatic cancer (hsa05212) | 4.09 × 10−3 | 4.03 × 10−2 | 8 | 18 |
| Wnt signaling pathway (hsa04310) | 4.19 × 10−3 | 4.03 × 10−2 | 12 | 21 |
| Cytokine-cytokine receptor interaction (hsa04060) | 4.52 × 10−3 | 4.15 × 10−2 | 14 | 20 |
FDR—false discovery rate.